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Administration of spironolactone provides a beneficial effect
in various animal models of renal injury. In this study, we
investigated whether spironolactone prevents the
progression of diabetic nephropathy through reduction of
connective tissue growth factor (CTGF) synthesis in type II
diabetic rats. In addition, we evaluated the effect of
aldosterone and spironolactone on CTGF and collagen
production in cultured cells. Renal functional and
morphologic changes were examined in Otsuka Long–Evans
Tokushima Fatty rats with or without spironolactone
treatment (20 mg/kg/day) for 8 months, as well as in
non-diabetic age-matched Long–Evans Tokushima Otsuka
rats. Spironolactone treatment did not induce any significant
differences in body weight, kidney/body weight ratio, serum
creatinine concentration, blood glucose levels, or systolic
blood pressure. However, urinary protein and albumin
excretion were significantly decreased in the spironolactone
treatment group, which was associated with amelioration of
glomerulosclerosis. In addition, renal CTGF, collagen
synthesis demonstrated marked decreases in the
spironolactone treatment group. In cultured MC and PTC,
aldosterone induced significant increases in CTGF gene
expression and protein synthesis associated with increased
collagen synthesis, which was abolished by prior treatment
with spironolactone. However, aldosterone treatment did not
induce transforming growth factor (TGF)-b1 overproduction,
and inhibition of TGF-b1 by neutralization of TGF-b1 protein
did not significantly prevent aldosterone-induced CTGF
production. These results suggest that the antifibrotic effects
of spironolactone may be mediated by CTGF through a
TGF-b1-independent pathway in this animal model of
diabetic nephropathy.
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Glomerulosclerosis and interstitial fibrosis are the final
common pathways of damage in renal diseases of diverse
etiology, including diabetic nephropathy.1–4 Connective tissue
growth factor (CTGF) is a novel cysteine-rich profibrogenic
protein, and it is also thought to be involved in the
development of glomerulosclerosis and interstitial fibrosis
in some renal diseases.5,6 CTGF mRNA and protein are
increased in a diabetic milieu, suggesting a role for CTGF in
the pathogenesis of diabetic glomerulosclerosis.7,8
The renin–angiotensin–aldosterone system has been im-
plicated in the progression of glomerulosclerosis, and
interruption of the renin–angiotensin–aldosterone system
retards the development of glomerulosclerosis and interstitial
fibrosis.9,10 Angiotensin II has received the most attention as
the mediator of injurious action in such circumstances.11
However, aldosterone has also been implicated as being an
injurious component of the renin–angiotensin–aldosterone
system in renal tissue.12,13
Aldosterone receptor blockade also provides beneficial
effects in patients with diabetic nephropathy.14 The hemo-
dynamic action remains a potential mechanism for the
progression of glomerulosclerosis and interstitial fibrosis.
However, non-hemodynamic actions of aldosterone are also
implicated in the development of renal fibrosis.15,16 However,
it is still unknown whether the renal protective effect of
spironolactone in diabetic nephropathy is related to a
reduction in CTGF production. As CTGF is an important
downstream factor mediating the fibrotic action of trans-
forming growth factor (TGF)-b1, it may be that aldosterone
affects CTGF regulation through the TGF-b1 pathway.8,17–20
However, it is not yet clear whether aldosterone-induced
CTGF regulation is mediated by TGF-b1 pathway.
For these reasons, we examined the effect of spironolac-
tone on renal function and morphologic changes in a type II
diabetic rat model and investigated whether spironolactone
suppresses renal injury through CTGF inhibition. To define
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the molecular mechanism of the renal protective effect of
spironolactone, we examined the effects of aldosterone and
spironolactone on CTGF and collagen synthesis in cultured
mesangial cells (MCs) and proximal tubular cells (PTCs). In
addition, we examined whether aldosterone-induced dys-
regulation of CTGF is mediated through TGF-b1-dependent
pathway in this situation.
RESULTS
Expression of 11b-hydroxysteroid dehydrogenase type 2 and
mineralocorticoid receptor in cultured MCs and MCTs
To confirm the aldosterone responsiveness of the MCs and
murine corticle tubule cells (MCTs), reverse transcription-
polymerase chain reaction (RT-PCR) was performed. For a
positive control, renal medullary tissue was used, owing to its
high expression of 11b-hydroxysteroid dehydrogenase type 2
(11b-HSD2) and mineralocorticoid receptor (MR). As shown
in Figure 1, 11b-HSD2 and MR were each expressed in both
MCs and MCTs, suggesting that both types of cells have high
aldosterone sensitivity.
Aldosterone induces CTGF and collagen synthesis through
TGF-b1-independent pathway in cultured MCs and MCTs
To observe the cytotoxic or proliferative effect of aldosterone,
an MTT (3-[4,5]dimethyl-2,5-diphenyltetrazolium bromide)
assay was performed. Even at a concentration of 100 nM,
aldosterone did not induce any cytotoxic or proliferative
effects in MCs and MCTs (Figure 2a and b). Aldosterone
induced an upregulation in CTGF gene transcription and
protein synthesis in a dose-dependent manner. Prior
treatment with spironolactone abolished aldosterone-in-
duced CTGF overproduction (Figure 3a–d). To explore
whether aldosterone could induce CTGF upregulation
through a TGF-b1-dependent pathway, we examined whether
aldosterone increase TGF-b1 gene expression and protein
synthesis, and evaluated the effect of neutralizing TGF-b1
antibody on CTGF production with aldosterone stimulation.
Aldosterone treatment did not increase TGF-b1 mRNA
expression and protein secretion, even at a concentration of
100 nM (Figure 3e). Furthermore, the production of CTGF
independent of the TGF-b1 pathway was further confirmed
by neutralization of TGF-b1 protein. As shown in Figure 3f,
CTGF mRNA expression and protein synthesis were
significantly increased even in the presence of TGF-b1-
neutralizing antibody. In addition, aldosterone induced a
significant increase in collagen gene expression and protein
production in a dose-dependent manner, and spironolactone
pretreatment significantly inhibited aldosterone-induced
collagen production in both MCs and PTCs (Figure 4a–d).
Spironolactone attenuates urinary protein excretion and
glomerulosclerosis in OLETF rats
Table 1 compares several biochemical parameters in the three
groups of rats. Body weight and plasma creatinine levels were
similar among the three groups, but the kidney/body weight
ratio, plasma glucose levels, and systolic blood pressure were
significantly higher in Otsuka Long–Evans Tokushima Fatty
(OLETF) rats than in Long–Evans Tokushima Otsuka
(LETO) rats. Treatment with spironolactone had no effect
on the kidney/body weight ratio, plasma glucose levels, and
systolic blood pressure. Urine volume and urinary sodium
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Figure 1 | PCR results for mineralocorticoid receptor and
11b-hydroxysteroid dehydrogenase 2 in cultured mesangial
cells and proximal tubular cells. Representative RT-PCR showing
442 and 280 bp products, which correspond to 11b-hydroxysteroid
dehydrogenase type 2 and mineralocorticoid receptor, respectively.
As a positive control, renal medulla from normal mice was used.
MC, mesangial cell; PTC, proximal tubule cell; 11b-HSD2, 11b-
hydroxysteroid dehydrogenase 2; MR, mineralocorticoid receptor.
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Figure 2 | Effect of aldosterone on cell viability in cultured cells.
Effect of different concentrations of aldosterone on cell viability in
(a) cultured mesangial cells and (b) proximal tubular cells. Quiescent
mesangial and proximal tubular cells were cultured in normal glucose
medium and treated with aldosterone at concentrations of 0.1, 1, 10,
100 pM, and 1, 10, 100 nM for 24 h. Cell viability was measured using
an MTT (3-[4,5-dimethylthiozol]-2,5-diphenyl tetrazolium bromide)
assay. Values are expressed as the percent compared with untreated
cells (n¼ 12 in each condition).
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Figure 3 | Effects of aldosterone on CTGF, mRNA expression and protein production in cultured mesangial cells and proximal tubular
cells. (a–b) Expression of CTGF mRNA was measured by real-time quantitative RT-PCR in (a) mesangial cells and (b) proximal tubular cells. Cells
were exposed to different concentrations of aldosterone with or without spironolactone for 24 h. (c–d) Representative Western blot analysis
showing the effect of aldosterone and spironolactone on the cell content of CTGF protein in (c) cultured mesangial cells and (d) proximal
tubular cells. (e–f) Effects of aldosterone on TGF-b1 mRNA expression and protein synthesis. (e) Cells were exposed to different concentrations
of aldosterone for 24 h, then TGF-b1 gene expression and secretory TGF-b1 protein levels were measured by RT-PCR and ELISA. Cells were
exposed to 100 nM of aldosterone with or without neutralizing TGF-b1 antibody at a concentration of 10 mg/ml for 24 h. (f) CTGF gene
expression and protein synthesis were measured by RT-PCR and Western blot. CTGF protein in cells was detected as a single band of
approximately 38 kDa. Twenty micrograms of protein were electrophoresed on 10% SDS-polyacrylamide gel. Data are shown as mean7s.d.
Aldo, aldosterone; Spiro, spironolactone; MC, mesangial cell; PTC, proximal tubule cell; *Po0.05, **Po0.01 vs control. #Po0.01 vs group with
aldosterone at concentration of 100 nM.
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and potassium excretion were not different between the three
groups. However, spironolactone treatment significantly
improved urinary protein excretion and urinary
albumin-to-creatinine ratio in OLETF rats.
Figure 5 shows representative histologic changes in the
experimental animals. Diabetic OLETF rats showed more
severe glomerulosclerosis compared with LETO rats. Spir-
onolactone treatment significantly reduced the degree of
glomerulosclerosis, compared with untreated OLETF rats
(Figure 5d). However, tubulo-interstitial fibrosis was not
remarkable, even in the OLETF rats, so that no major
differences in this regard were found between the three
groups. Concerning the relationship between plasma aldo-
sterone levels and other biochemical measurements, plasma
aldosterone levels appeared to be positively correlated with
plasma glucose levels (r¼ 0.372, P¼ 0.039) (Figure 6).
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Figure 4 | Effects of aldosterone and spironolactone on type I and type IV collagen mRNA expression and protein production in
cultured mesangial and proximal tubular cells. (a–b) Expression of procollagen a1(I) and procollagen a1(IV) mRNA was measured by real-
time quantitative reverse transcriptase-PCR in (a) mesangial cell and (b) proximal tubule cell. Cells were exposed to different concentrations of
aldosterone with or without spironolactone for 24 h. (c–d) Total soluble collagen was measured from culture supernatants by the soluble
collagen assay kit. (c) Mesangial cells and (d) proximal tubular cells were exposed to different concentrations of aldosterone with or without
spironolactone for 24 h. Total soluble collagen content was corrected by total cellular protein content. Data are shown as mean7s.d. Aldo,
aldosterone; Spiro, spironolactone. *Po0.05, **Po0.001 vs control. #Po0.001 vs group with aldosterone at a concentration of 100 nM.
Table 1 | Biochemical parameters in experimental groups
LETO OLETF OLETF+spironolactone
Body weight (g) 5907107 5957137 568798
Kidney weight (mg)/BW (g) 103 2.670.1 4.271.1* 3.771.4*
SBP (mm Hg) 101710 150714* 139710*
Urine volume (ml/day) 11.078.2 22.577.5 17.5713.9
P-glucose (mg/dl) 16678 4027112* 378775*
P-Cr (mg/dl) 0.670.0 0.570.1 0.770.1
P-aldosterone (pg/ml) 263763 4547147 6187210*
U-protein (mg/mg Cr) 0.570.1 16713* 6.574.0*,#
U-MA (mg/mgCr) 28.11711.46 497.657196.44** 332.817107.12**,#
U-Na (mmol/day) 1.2170.04 1.2970.51 1.2270.64
U-K (mmol/day) 2.5670.67 2.3571.08 2.0570.97
BW, body weight; P-Aldosterone, plasma aldosterone concentration; P-Cr, plasma creatinine concentration; P-Glucose, plasma glucose concentration; SBP, systolic blood
pressure; U-K, urinary potassium; U-MA, urinary albumin excretion; U-Na, urinary sodium; U-Protein, urinary protein excretion.
Values are expressed as mean7s.d. *Po0.05, **Po0.01 vs LETO; #Po0.05 vs OLETF.
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Spironolactone attenuates CTGF, as well as type 1 and type
IV collagen expression in OLETF rats
RT-PCR analysis of the renal cortex demonstrated signifi-
cantly higher level of CTGF mRNA expression in OLETF rats
when compared to LETO rats. As with the in vitro data,
treatment with spironolactone significantly attenuated CTGF
mRNA expression in OLETF rats (Figure 7a). CTGF protein
expression was also significantly increased in OLETF rats,
whereas it was rarely observed in LETO rats. CTGF
immunoreactivity was mainly detected in the distal tubular
epithelial cells and some proximal tubular epithelium. The
pattern of CTGF immunostaining in the glomeruli was
negligible in LETO rats, but CTGF protein expression was
increased in the glomerular mesangium and in some
podocytes in OLETF rats. Spironolactone treatment inhibited
CTGF protein expression in kidneys of OLETF rats (Figure
7b–e).
Renal cortical mRNA expression of collagen demonstrated
a significantly higher level of expression in OLETF rats
compared with LETO rats. As seen in the CTGF studies, the
spironolactone treatment group showed significantly de-
creased levels compared with those of OLETF rats (Figure 8a
and b). The increase in collagen expression in diabetic rats
was mainly observed in the glomerular mesangium and in the
peritubular interstitial tissues. As with the in vitro data, the
spironolactone treatment group showed decreased collagen
protein expression when compared with untreated OLETF
rats (Figure 8c–j).
DISCUSSION
Despite much interest in the role of aldosterone and CTGF in
renal fibrosis, the direct relationship between these two
molecules has been unclear. In the present study, we first
provide evidence that aldosterone increased CTGF, as well as
type 1 and type IV collagen production, in a dose-dependent
manner in cultured MCs and PTCs. We then demonstrate
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Figure 7 | Renal expression of CTGF mRNA and immunohisto-
chemistry of CTGF protein in experimental animals. (a) Renal
cortical mRNA gene expression was measured by real-time RT-PCR.
Immunohistochemistry of CTGF in experimental animals. (b) LETO rat
at 52 weeks of age; (c) OLETF rat at 52 weeks of age; (d) OLETF rat
treated with spironolactone at 20 mg/kg/day for 8 months at 52
weeks of age; and (e) immunostaining score for CTGF in the
glomeruli and tubulo-interstitial tissues in the experimental group.
Positive staining for CTGF was mainly detected in the glomerular
mesangium and peritubular interstitial tissues in diabetic rats (short
arrow). Original magnification  400. Data are shown mean7s.d.
*Po0.01 vs LETO. #Po0.05 vs OLETF.
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Figure 5 | Representative renal histologic findings in experimental
animals. (a) LETO rat at 52 weeks of age; (b) OLETF rat at 52 weeks of
age; (c) OLETF rat treated with spironolactone at 20 mg/kg/day for 8
months at 52 weeks of age; and (d) glomerulosclerosis index in each
group. Whole-kidney average glomerulosclerosis index was obtained
from specimens by averaging scores from all glomeruli on one
section. Original magnification  100; PAS stain. Data are shown
mean7s.d. **Po0.01 vs LETO. #Po0.05 vs OLETF.
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Figure 6 | Correlation coefficent between plasma aldosterone
concentration and plasma glucose levels. Plasma aldosterone
levels showed a weak but significant positive correlation with plasma
glucose levels.
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that aldosterone blockade by spironolactone inhibited the
aldosterone-induced CTGF and increased collagen produc-
tion. More importantly, we have also demonstrated that
spironolactone treatment decreases urinary protein and
albumin excretion, and inhibits the glomerulosclerosis
associated with attenuation of CTGF, as well as type I and
type IV collagen expression in an animal model of type II
diabetes mellitus.
There is considerable experimental evidence that aldoster-
one contributes to the development of renal fibrosis in
various animal experimental models.12,13,21,22 In addition,
recent clinical trials have suggested the possibility that
inhibition of the aldosterone system may have additional
beneficial effects that are independent of renin–angiotensin
blockade in diabetic nephropathy.14,16,23,24
Our observation that aldosterone upregulates CTGF
expression in cultured cells is in agreement with a recent
microarray study of another group which added CTGF to the
list of early aldosterone-response genes.25 Our results here
strongly suggest that the classical genomic action of
aldosterone is involved in CTGF synthesis, based on the
inhibition of CTGF synthesis by spironolactone, an MR
antagonist. In addition, our observation that spironolactone
abolished aldosterone-induced CTGF overproduction in
PTCs may explain in part the previously reported
beneficial effect of spironolactone in animal models of renal
injury.26,27
Recently, several reports have suggested that aldosterone
can affect MCs.28–30 Aldosterone stimulates proliferation of
MCs by activating mitogen-activated protein kinase,28 and
chronic administration of aldosterone to rats induces
glomerular mesangial injury.29 Moreover, in support of the
role of aldosterone, MCs produce aldosterone in response to
low-density lipoprotein and angiotensin II.30 These findings
indicate that glomerular MCs are an aldosterone-producing
tissue, as well as being a potential target for the injury
induced by aldosterone, and may have pathogenic role in the
progression of glomerular injury.
In the present study, we show that aldosterone modulates
some of the important profibrotic mediators in MCs. For
instance, MCs have both 11b-HSD2 and MR, which suggests
that MCs have high aldosterone sensitivity.31 Although we
could not find any proliferative effect of aldosterone, CTGF
expression and collagen synthesis were significantly upregu-
lated by aldosterone treatment, which was abolished by
spironolactone.
Another important finding of this study is that aldoster-
one induced CTGF production through a TGF-b1-indepen-
dent pathway. We did not observe any significant increase in
TGF-b1 gene expression and protein synthesis in response to
aldosterone stimulation. Furthermore, the fact that inhibition
of TGF-b1 by the use of neutralizing TGF-b1 antibody did
not affect aldosterone-induced CTGF synthesis suggests that
aldosterone directly induced CTGF overproduction through
a TGF-b1-independent pathway. These results are in contrast
with some previous studies showing a TGF-b1-dependent
pathway for CTGF synthesis.8,17–20 However, these studies
used different models, and it is still unknown whether
aldosterone-induced CTGF overproduction occurs in a TGF-
b1-dependent manner.
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Figure 8 | Renal expression of collagen type I and type IV mRNA
and immunohistochemistry of collagen type I and type IV protein
in experimental animals. (a–b) Renal cortical mRNA gene expression
(a) for procollagen a1 type I collagen and (b) procollagen a1 type IV
collagen was measured by real-time RT-PCR. (c–h) Immunohisto-
chemistry of (c–e) type I collagen and (f–h) type IV collagen in
experimental animals. (c and f) LETO rat at 52weeks of age; (d and g)
OLETF rat at 52 weeks of age; OLETF rat treated with spironolactone
at 20 mg/kg/day for 8 months at 52 weeks of age (e and h).
Immunostaining score for (i) type I collagen and (j) type IV collagen in
the glomeruli and tubulo-interstitial tissues. Positive staining for
collagen type I and collagen type IV was mainly observed in the
glomerular mesangium and in the peritubular interstitial tissues
(short arrow). Original magnification  400. Data are shown as
mean7s.d. *Po0.05, **Po0.01 vs LETO. #Po0.05, ##Po0.01 vs
OLETF.
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Recent clinical trials have suggested that inhibition of the
aldosterone system may have an additional beneficial effect in
diabetic nephropathy.14,32 However, little in vivo evidence is
available concerning the potential mechanisms of aldosterone
blockade in type II diabetes mellitus. Fujisawa et al.16 first
reported that spironolactone ameliorated renal fibrosis via
the inhibition of macrophage infiltration, plasminogen
activator-1 expression, and TGF-b1 expression in strepto-
zotocin-induced early diabetic rat. However, they investigated
changes in the early stage of diabetic nephropathy and did
not observe the direct effect of spironolactone upon intrinsic
renal cells.
In the present study, we observed changes in glomerular
injury and urinary albumin excretion, as well as in CTGF, and
collagen expression in the late stages of diabetic nephropathy
in type II diabetic rats. In agreement with a previous report,16
glomerulosclerosis was significantly higher in diabetic rats,
and spironolactone treatment ameliorated this glomerular
injury. We also noted that renal CTGF, and collagen mRNA
and protein expression were significantly higher in the
diabetic kidney, and that spironolactone treatment markedly
suppressed the expression of these profibrotic mediators.
Although increased CTGF and collagen synthesis in the
diabetic kidney may be aggravated by the activation of
multiple cytokines and growth factors such as TGF-b,
suppression of these molecules by spironolactone suggests
that aldosterone may contribute in part to the overproduc-
tion of CTGF and collagen in the diabetic kidney.
Treatment with spironolactone did not affect systolic
blood pressure, plasma glucose levels, or kidney to body
weight ratios in OLETF rats. This suggests that the beneficial
effect of spironolactone is independent of hemodynamic and
metabolic mechanisms. However, in this study, we only
measured blood pressure at the end of the study period, so
we cannot exclude the possibility that blood pressure had
been lower during the study period in the spironolactone-
treated group. Additional hemodynamic factors may operate
as a beneficial effect of spironolactone treatment.
In conclusion, spironolactone treatment decreased urinary
albumin excretion and prevented glomerulosclerosis. One of
the molecular mechanisms of spironolactone treatment,
overproduction of CTGF, and type 1 and type IV collagen
expression was significantly decreased by spironolactone
treatment in this animal model of type II diabetic nephro-
pathy. Furthermore, spironolactone treatment abolished
aldosterone-induced CTGF and collagen synthesis in cultured
MCs and PTCs through a TGF-b1-independent manner.
Taken together, these results suggest that blockade of the
aldosterone system may be a new therapeutic target for
retarding the progression of diabetic nephropathy.
MATERIALS AND METHODS
Animals
We used age-matched male OLETF and LETO rats bred at the
Tokushima Research Institute (Otsuka Pharmaceutical Co., Tokyo,
Japan).33,34 Rats at 20 weeks of age were divided into three groups
(N¼ 5/group): Group 1 consisted of LETO control rats; Group 2
animals were OLEFT type II diabetes rats; and Group 3 consisted of
OLETS rats treated for 8 months with 20 mg/kg/day of spirono-
lactone (Pharmacia Corp., Peapack, NJ, USA) mixed into standard
chow. This dose of spironolactone is sufficient for blocking the
actions and specific binding of aldosterone to MR during in vivo
kinetic analysis.35 Rats had free access to rat chow and tap water, and
were caged individually within a temperature and light-controlled
environment. At the end of the study period, systolic blood
pressures were measured using tail-cuff plethysmography. The
urinary protein and albumin concentration were corrected using
the urinary creatinine concentration. The urinary protein was
measured by nephelometry, and the urinary albumin was deter-
mined by a competitive enzyme-linked immunosorbent assay
(ELISA) kit (Shibayagi, Shibukawa, Japan). Plasma glucose levels
were measured by a glucose oxidase method, and creatinine levels
were determined by a modified Jaffe method. Plasma aldosterone
concentrations were measured by a radioimmunoassay kit (Coat-A-
Counts kit, DPC, Los Angeles, CA, USA). We killed rats under
anesthesia by intraperitoneal injection of sodium pentobarbital,
50 mg/kg body weight. One kidney of each rat was removed and
weighed, and two slices of the other kidney were fixed in 4%
paraformaldehyde solution for 24 h followed by 70% ethanol and
embedded in paraffin. Experiments were conducted in accordance
with Korea University Guide for Laboratory Animals.
Histology and immunohistochemistry
The kidney tissues embedded in paraffin were cut into 4 mm thick
slices, and were used for periodic acid-Schiff and immunohisto-
chemistry for CTGF, as well as type I and type IV collagen proteins.
A semiquantitative score for a sclerosis index was used to evaluate
the degree of glomerulosclerosis on periodic acid-Schiff-stained
sections. The severity of sclerosis for each glomerulus was graded
from 0 to 4þ as follows: 0, no lesion; 1þ , sclerosis ofo25% of the
glomerulus; 2þ , 3þ , and 4þ sclerosis of 25 as 50%, 450 to 75%,
and 475% of the glomerulus, respectively. All histologic examina-
tions were carried out by two pathologists in a blinded manner,
according to the method described by Ma et al.36 More than 80
glomeruli were analyzed in kidney sections from each rat, and
these scores were compared between age-matched OLETF and
LETO rats.
For immunohistochemical staining, renal tissue was placed on
standard commercial microscopic slides. After removal of the
paraffin and dehydration in xylene followed by graded alcohols, the
slides were immersed in distilled water. They were then transferred
to a 1 M ethylenediaminetetraacetic acid buffer solution (pH 8.0) and
microwaved for 10 min for antigen retrieval. H2O2 (3.0%) in
phosphate-buffered saline was applied to the slides for 10 min to
block endogenous peroxidase; the slides were incubated at room
temperature for 20 min immersed in normal goat serum. Next, they
were incubated for 1 h with primary antibodies against rabbit
polyclonal anti-CTGF (1:200; Abcam, Cambridge, UK), mouse
monoclonal anti-type 1 collagen (1:200; Abcam, Cambridge, UK)
and rabbit polyclonal anti-type IV collagen (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The slides were then
incubated in secondary antibody (CSA kit, DAKO, Carpinteria,
CA, USA) for 30 min. For coloration, slides were incubated at room
temperature with a mixture of 0.05% 3,30-diaminobenzidine
containing 0.01% H2O2, counterstained with Mayer’s hematoxylin.
Negative control sections were stained under identical conditions
with the buffer solution substituting for the primary antibody.
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For the evaluation of CTGF, as well as type I collagen and type IV
collagen staining, glomerular or tubulo-interstitial fields were
graded semiquantitatively. Briefly, each score reflects both changes
in the extent and the intensity of staining and graded on a five-scale
basis: Grade 0, very weak or absent staining and no localized
increases of staining; Grade 1, diffuse, weak staining with 1–25% of
the glomerulus showing focally increased staining; Grade 2, 25–50%
of the glomerulus demonstrating focal, strong staining; Grade 3,
50–75% of the glomerulus stained strongly in a focal manner; and
Grade 4, more than 75% of the glomerulus stained strongly. From
50 to 60 glomeruli and 20 consecutive interstitial fields, including
tubular segments, were counted under high power fields ( 400)
and an average score was calculated.
Mesangial and MCT cultures
A portion of the renal cortex from normal C57BL/6 mice was
obtained immediately following surgical nephrectomy. MCs were
cultured at 371C in 5% CO2–95% air in Dulbecco’s modified Eagle’s
medium supplemented with 17% fetal calf serum, 2% each of
penicillin and streptomycin, 1% HEPES, 2 g sodium bicarbonate,
and 2 mM L-glutamine.
MCT cells are a cultured line of PTCs harvested originally from
the renal cortex of SJL mice and functionally characterized by
Haverty et al.37 (generous gift from Eric G Neilson, Vanderbilt
University, Nashville, TN, USA). Confluent MCs and MCTs were
serum-starved for 24 h, and then different concentrations of
aldosterone (Sigma-Aldrich, St Louis, MO, USA) were added to
the culture media at final concentrations of 1, 10, and 100 nM. When
the effects of spironolactone (Sigma-Aldrich, St Louis, MO, USA)
were tested, these compounds were added to cells at a concentration
of 100 nM 1 h before aldosterone treatment (100 nM). To determine
whether aldosterone-induced CTGF upregulation is mediated by
TGF-b1, TGF-b1 gene expression and protein synthesis was
examined in response to different concentrations of aldosterone.
To further confirm the dependency of CTGF synthesis on the TGF-
b1 pathway, anti-TGF-b1-neutralizing antibody (Genzyme, Cam-
bridge, MA, USA) was administered 1 h before aldosterone
treatment at a final concentration of 10mg/ml. All experimental
groups were cultured in triplicate and harvested at 24 h for
extraction of total RNA and protein.
Cell viability assay (3-[4,5-dimethylthiozol]-2,5-diphenyl
tetrazolium bromide assay)
A modified colorimetric assay was used to quantify cell viability.
Briefly, confluent cells were cultivated on 96-well tissue culture
plates and made quiescent in serum-deprived conditions for 24 h.
Cells were then incubated for 24 h in normal glucose medium with
or without different concentrations of aldosterone (0.1 pM –100 nM).
The solubilized formazan product was then measured in an ELISA at
570 nm.
RNA extraction and analysis of gene expression by real-time
quantitative PCR
Total RNA was extracted from renal cortical tissue and from
cultured cells with Trizol reagent and further purified using an
RNeasy Mini kit (Qiagen, Valencia, CA, USA), following the
manufacturer’s instruction. Primers were designed from the
respective gene sequences using the Primer 3 software, and
templates secondary structures were examined and excluded using
an mfold software program. The sequence of each primer is shown
in Table 2. Quantitative gene expression was performed on a Bio-
Rad iCycler system (Bio-Rad, Hercules, CA, USA) using SYBR
Green technology. Total mRNA was reverse-transcribed into cDNA
using an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA).
The specificity of each PCR product was evaluated by melting curve
analysis, followed by an agarose gel electrophoresis to confirm the
Table 2 | Primer sequences for real-time quantitative PCR
Target gene Primer sequence (50–30) Amplicon length (bp)
Mouse CTGF, forward TGG CGA GAT CAT GAA AAA GA 103
Mouse CTGF, reverse AGA TGT CAT TGT CCC CAG GA
Mouse PCa1(I), forward CCA AAG GTG CTG ATG GTT CT 107
Mouse PCa1(I), reverse ACC AGC TTC ACC CTT GTC AC
Mouse PCa1(IV), forward GCT CTG GCT GTG GAA AAT GT 102
Mouse PCa1(IV), reverse CTT GCA TCC CGG GAA ATC
Mouse TGF-b1, forward AGC CCG AAG CGG ACT ACT AT 97
Mouse TGF-b1, reverse CTG TGT GAG ATG TCT TTG GTT TTC
Mouse b-actin, forward GGA CTC CTA TGT GGG TGA CG 103
Mouse b-actin, reverse CTT CTC CAT GTC GTC CCA GT
Rat CTGF, forward GGC AGG GCC AAC CAC TGT GC 167
Rat CTGF, reverse CAG TGC ACT TGC CTG GAT GG
Rat PCa1(I), forward ACC TGG CAT TAA GGG GAA TC 142
Rat PCa1(I), reverse TCC AGT CCT TCC TTG GTC AC
Rat PCa1(IV), forward TAG GTG TCA GCA ATT AGG CAG G 484
Rat PCa1(IV), reverse CGG ACC ACT ATG CTT GAA GTG A
Rat b-actin, forward GCG CAA GTA CTC TGT GTG GA 89
Rat b-actin, reverse CAT CGT ACT CCT GCT TGC TG
Mouse 11b-HSD2, forward ACT GGC CTG TGG GGT CTG GTT A 442
Mouse 11b-HSD2, reverse GCC CGT GCA CGT GCT CAA TGT A
Mouse MR, forward GTG GAC AGT CCT TTC ACT ACC G 280
Mouse MR, reverse TGA CAC CCA GAA GCC TCA TCT C
11b-HSD2, 11b-hydroxy-steroid dehydrogenase type 2(11b-HSD2); CTGF, connective tissue growth factor; MR, mineralocorticoid receptor; PCa1(I), pro-collagen a1 chain in
type I collagen; PCa1(IV), pro-collagen a1 chain in type IV collagen; TGF-b1, transforming growth factor-b1.
In this experiment, each sample was run in triplicate and the corresponding non-reverse-transcribed mRNA sample was used as a negative control. The mRNA level of each
sample was normalized to that of b-actin mRNA.
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single clean band. The real-time RT-PCR was performed by running
for 10 min at 501C and 5 min at 951C. Subsequently, 45 cycles
consisting of denaturation for 10 s at 951C, and annealing with
extension for 30 s at 601C, were applied. At the end of the PCR cycle,
samples were heated to 951C to check that a single PCR product was
obtained. The mRNA level of each sample was normalized to that of
b-actin mRNA.
RT-PCR for expression of 11b-HSD2 and MR in cultured MCs
and MCTs
To identify the presence of 11b-HSD2 and MR, which are important
for expressing aldosterone responsiveness in tissue,31 tissue samples
were examined by RT-PCR. The sequence of each primer is shown
in Table 2. The PCR conditions consisted of initial denaturation at
941C for 7 min, followed by 35 cycles (11b-HSD2) or 34 cycles (MR)
of denaturation at 941C for 1 min, annealing at 581C for 1 min,
extension at 721C for 1 min, and final extension at 721C for 7 min.
Western blotting of CTGF in cultured MCs and MCTs
Cells were lysed in lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH
8.0, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride), and
protein concentration was measured by bicinchoninic acid protein
assay (Pierce, Rockford, IL, USA). Twenty micrograms of each
protein sample were electrophoresed on 10% SDS-polyacrylamide
gel under denaturing conditions. The proteins were transferred onto
a polyvinylidene difluoride membrane for 120 min at 250 mA. After
the filter was blocked by incubating the membranes with blocking
solution for 1 h at room temperature, the membrane was hybridized
with rabbit polyclonal anti-CTGF antibody (Abcam, Cambridge,
UK) or mouse monoclonal anti-b-actin antibody (Sigma-Aldrich, St
Louis, MO, USA) diluted 1:1000 for CTGF and 1:5000 for b-actin in
blocking buffer overnight at 41C. The filter was then incubated with
horseradish peroxidase-conjugated secondary antibody diluted
1:1000 for 60 min at room temperature. Specific signals were
detected using the enhanced chemiluminescence method (Amer-
sham, Buckinghamshire, UK).
Measurement of TGF-b1 protein in culture supernatant
The amount of TGF-b1 secreted into the culture medium was
quantified using a commercially available ELISA kit (R&D systems,
Abingdon, OX, UK) following the manufacturer’s instructions. Total
(active plus latent fractions) TGF-b1 was measured following acid
activation with 1N HCl for 10 min at room temperature, followed by
neutralization with 1.2 N NaOH/0.5 M HEPES. Samples were applied
to microtiter plates that had been precoated with TGF-b1. After 2 h
of incubation, they were washed three times and horseradish
peroxidase-conjugated anti-TGF-b1 antibody was applied to each
well for 2 h at room temperature. The plates were then washed five
times, and developed with 100 ml of color reagent/well. The intensity
of the color was measured in an ELISA reader at 450 nm. To control
for the difference in cell numbers between wells, the concentration
was corrected based on the amount of total cell protein.
Measurement of secreted collagen in cultured MCs and MCTs
Total soluble collagen was measured in culture supernatants by the
SircolTM soluble collagen assay kit (Biocolor, Belfast, Northern
Ireland), following the manufacturer’s instructions. Briefly, 1 ml of
Sirius red reagent was added to 100 ml of test samples and mixed for
60 min at room temperature in a mechanical shaker. The
collagen–dye complex was precipitated by centrifugation at
14 000 g for 10 min. To release the bound dye, 1 ml of alkali reagent
(0.5 M NaOH) was added to the precipitate, and then the absorbance
was measured at 540 nm using an ELISA reader.
Statistical analysis
We used non-parametric analysis owing to the few sample numbers.
Results were expressed as mean7s.d. A Kruskall–Wallis test was used
for comparison of more than two groups, followed by a
Mann–Whitney U-test for comparison using a microcomputer-
assisted program with SPSS for Windows 10.0 (SPSS Inc., Chicago,
IL, USA). Correlations between plasma aldosterone levels and
plasma glucose levels were examined by Spearman’s rank correla-
tion. A Po0.05 was considered statistically significant.
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